OMONTYS PRESERVATIVE FREE
Post-LOENDAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Mar 2012
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMONTYS PRESERVATIVE FREE is a small-molecule therapeutic administered intravenously or subcutaneously as a solution formulation. The specific indication and mechanism of action are not disclosed in available data, limiting clinical characterization. The preservative-free designation suggests a refined formulation addressing patient safety or tolerability concerns.
Post-LOEPost-LOE
Product is in post-loss-of-exclusivity phase with 35% competitive pressure; commercial team likely focused on cost-containment and niche positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on OMONTYS PRESERVATIVE FREE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.